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ALTEPLASE: THE CLOT-BUSTER
INTRODUCTION:

Mayer Goldberg

The human body is defined by many complex and inconsistent characteristics. For
example, the body forms blood clots in traumatic events, but blood clots are likewise
associated with hazardous or fatal conditions. Platelets are small cells, derived from the
precursor megakaryocytes, which are responsible for blood clotting to prevent bleeding from
a ruptured blood vessel. Platelets fasten to each other and release a coagulation factor that
solidifies around the ruptured area to prevent blood loss. A subordinate quantity of platelets
can result in excessive bleeding. However, high platelet numbers can progress into blood
clots, which may potentially be dangerous because they produce a condition known as
thrombosis. Thrombosis precedes harmful conditions such as stroke, myocardial infarction,
pulmonary embolism, and other conditions associated with the disruption of circulatory blood
flow.
Depending on the severity of the condition, there are different treatments available for
thrombosis. Some patients may require surgery for an illness caused by thrombosis. In other
instances, there are thrombolytic or fibrinolytic drugs that can be used as medicinal therapy to
dissolve blood clots. Thrombolytic drugs disintegrate blood clots by converting plasminogen
into plasmin. The plasmin, a serine protease, actually does the blood clot dissolving. The most
important thrombolytic drug categories include tissue plasminogen activator and
streptokinase (Klabunde 2005). While there are two significant families of thrombolytic
medications that can be utilized in thrombolytic therapy, alteplase, a recombinant tissue
plasminogen activator, is the preferred medication for treatment of acute ischemic stroke,
myocardial infarction with ST elevation, and, in some rare cases, pulmonary embolism.

DISCUSSION:
THROMBOLYTIC THERAPY FOR STROKE

For approximately a decade, stroke has been the third leading cause of death in the
United States following cardiac diseases and cancer. Roughly 137,000 Americans die from
stroke every year (Center for Disease Control 2009). Since stroke can cause brain cell damage
or cell death, patients often exhibit sudden numbness or paralysis of the face, legs, or arms.
Thus, stroke is the primary cause of permanent disabilities. There are two general
classifications of stroke: ischemic strokes and hemorrhagic strokes.
ISCHEMIC STROKES
Almost 90% of strokes are ischemic strokes, caused by decreased blood flow to the
brain (Swanson 1998b). Whenever normal blood flow to the brain is interrupted, the neurons
begin to die within minutes. Since brain cells require oxygen for survival, and they acquire
oxygen from red blood cells, they begin to decline in function (see figure 1). There are two
subcategories of ischemic strokes: thrombotic and embolic. A thrombotic stroke is caused by
the formation of a blockage, thrombus, in one of the arteries supplying the brain with blood. A
thrombus forms from arteriosclerosis, which is created by an accumulation of fatty deposits.
An embolic stroke occurs when the body carries a blood clot from an alternate origination to a
blood vessel in the brain. For example, atrial fibrillation in one of the two upper chambers in
the heart can proceed to the formation of a blood clot that will travel elsewhere in the body.
Thrombolytic drugs are utilized in ischemic strokes to bust open the thrombus or embolus. In
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the 1980s, the first drug developed for the treatment of stroke was streptokinase, but this
medication was abandoned after it caused unacceptable incidence of cerebral hemorrhage
(Saver and Lutsep 1995). Alteplase was developed, and research found it to be a safer and
more efficient choice for thrombolytic therapy in ischemic stroke patients. An alternate study
showed the efficacy of alteplase administered to acute ischemic stroke patients up to four
hours after the onset of symptoms.

Figure 1: Ischemic Stroke: The illustration shows how an ischemic stroke can occur in the brain. If a
blood clot breaks away from plaque buildup in a carotid (neck) artery, it can travel to and lodge in an
artery in the brain. The clot can block blood flow to part of the brain, causing brain tissue death.
Source: http://www.nhlbi.nih.gov/health/dci/images/stroke_ischemic.jpg

Patients were admitted or excluded from the alteplase clinical trial based on various
elements. Some of the inclusion criteria for the acute ischemic stroke trial were the ability to
have the study drug administered between 3 and 4.5 hours after the onset of stroke symptoms
and the presence of stroke symptoms for at least 30 minutes with no significant improvement.
Some rejection criteria were intracranial hemorrhage, seizures at the onset of stroke, and
serious head injury within the previous three months. For a complete list of selective and
dismissive criteria see table 1(Hacke et al. 2008).
A total of 821 patients enrolled in the trial and were randomly assigned to either the
alteplase group or a placebo group. The alteplase group had 418 patients, and the placebo
group had 403 patients. Approximately 82 patients were administered the drug or a placebo
between 3 and 3.5 hours, 384 patients obtained it between 3.5 and 4 hours, and 322 received it
between 4 and 4.5 hours. Of the remaining patients, treatment time for 12 patients from the
alteplase group and 15 patients from the placebo group were not obtainable. Additionally, one
patient from the alteplase group and five patients from the placebo group were administered
treatment after 4.5 hours. The trial result was a ratio of 41.6% to 36.7% in favor of the
alteplase group. Although the results indicated more symptomatic intracranial hemorrhage
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Table 1: Major exclusion and inclusion criteria.

Source: Hacke et al. 2008

in the alteplase group than in the placebo group, the overall outcome of the trial showed a
more favorable result for the alteplase group in the 4.5 hours range. This indicates that
supplying alteplase intravenously can clinically better the condition of ischemic stroke patients
up until 4.5 hours following the incipience of symptoms (Hacke et al. 2008).
HEMORRHAGIC STROKES
Hemorrhagic strokes take place following a rupture or leak from a blood vessel in the
brain (Figure 2). There are two subdivisions of hemorrhagic strokes: intracerebral
hemorrhage and subarachnoid hemorrhage (Swanson 1998a). In an intracerebral
hemorrhagic stroke, a blood vessel bursts causing blood seepage into brain tissue. The sudden
increase in pressure within the brain can cause cellular damage. Furthermore, the brain cells
beyond the ruptured blood vessel are damaged due to the interruption of blood flow and
oxygen delivery. A subarachnoid hemorrhagic stroke is caused by leakage from a blood vessel
into the space between the surface of the skull and the brain. Hemorrhagic strokes are not
treated with thrombolytic therapy because of the major risk of further hemorrhaging.
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Figure 2: Hemorrhagic Stroke: The illustration shows how a hemorrhagic stroke can
occur in the brain. An aneurysm in a cerebral artery breaks open, which causes bleeding
in the brain. The pressure of the blood causes brain tissue death.
Source: http://www.nhlbi.nih.gov/health/dci/images/stroke_hemorrhagic.jpg

THROMBOLYTIC THERAPY FOR MYOCARDIAL INFARCTION
Major heart disease is the leading cause of death in the United States. According to
the CDC, nearly 48% of all deaths reported in 2010 were cardiac related. Heart attack, also
known as acute myocardial infarction, happens when there is an interruption of the blood

Figure 3: Heart with Muscle Damage and a Blocked Artery: Figure A shows a heart with dead heart
muscle caused by a heart attack. Figure B is a cross-section of a coronary artery with plaque buildup and a
blood clot.
Source: http://www.nhlbi.nih.gov/health/dci/images/heart_coronary_artery.gif
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flow to the heart, causing the cardiac muscles to die (Pub Med Health 2010a). Many heart
attacks are caused by blood clots forming an obstruction in one of the coronary arteries,
which carries blood and oxygen to the heart tissues. The blockage disrupts the oxygen flow to
heart tissues, causing heart muscle cell death (Figure 3). Atherosclerosis, a principle cause of
blockages, is the accretion of plaque that adheres to the coronary artery walls and forms an
occlusion. The plaque may tear, and blood platelets may fasten to it forming a thrombus (Pub
Med Health 2010a). A myocardial infarction (MI) can be classified as a non-ST elevation MI
or an ST elevation MI based on electrocardiogram changes (Cleveland Clinic 2009).
MYOCARDIAL INFARCTION WITH NON -ST SEGMENT ELEVATION
A non-ST elevation MI does not exhibit changes on an electrocardiogram.
Additionally, the extent of damage is minimal since the artery is only partially obstructed
(Cleveland Clinic 2009). According to the American Heart Association, there is a close
correlation between non-ST elevation MI and unstable angina. Unstable angina is a condition
caused by a diminished supply of blood flow and oxygen to the heart; as research indicates, it
can be an introduction to a heart attack (Pub Med Health 2010b). Non-ST elevation MI and
unstable angina are treated by anti-platelet agents, anti-thrombin agents, or anti-ischemic
agents (Jevon et al. 2008). Although the treatments for non-ST elevation myocardial
infarction and unstable angina are similar, there is a different course of action taken for a
myocardial infarction with ST elevation.
MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION
An ST-elevation MI is caused by the prolonged obstruction of blood supply that
affects a large portion of the heart. Thus, ST segment changes on an electrocardiogram are
clearly visible and are easily detected (Cleveland Clinic 2009). If ST-elevation MI is detected
early enough, thrombolytic treatment can be an essential part in its treatment as thrombolytics
restore blood flow, thus decreasing casualties. Thrombolytic treatment is the preferred
treatment for ST segment myocardial infarction, because it is the most effective at achieving
reperfusion. Thrombolytic treatment can effectively restore blood flow when administered
within 12 hours of symptom onset, but maximum benefit is obtained when administered
promptly (Hilleman et al. 2007).
The Global Utilization of Streptokinase and Tissue Plasminogen Activator for
Occluded Coronary Arteries, known as the Gusto-I trial, was conducted to compare the
efficacy of streptokinase and alteplase in ST segment myocardial infarction. Additionally, the
study determined whether earlier and sustained reperfusion with alteplase improves the
survival rate in people with acute myocardial infarction. A total of 41,021 patients within six
hours of the onset of acute myocardial infarction with ST segmentation were randomly
assigned to one of four thrombolytic treatments: streptokinase, streptokinase with intravenous
heparin, accelerated tissue plasminogen activator, or tissue plasminogen activator with
intravenous heparin. The primary follow-up and end point of the trial was 30 days (Hacke et
al. 2008).
After the 30 days, the results indicated that patients receiving accelerated tissue
plasminogen activator had a more significant reduction in mortality during the 30-day period
than those administered streptokinase and any other combined strategies. There was,
however, an increase of hemorrhagic stroke episodes in accelerated tissue plasminogen
activator patients above the others. Still, the overall endpoint of death or permanent disability
was lower in patients administered accelerated tissue plasminogen activator than in patients
administered any other combination. A Gusto-III trial was soon established to determine if
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reteplase, a newer recombinant tissue plasminogen activator, was better than alteplase. More
than 15,000 patients, all within six hours of the onset of symptoms, entered the trial. The 30day mortality rate for reteplase did not exhibit any additional survival benefits in acute
myocardial infarction (Hacke et al. 2008).

THROMBOLYTIC THERAPY FOR PULMONARY EMBOLISM
A pulmonary embolism is an occluded artery that disrupts the blood flow to the lungs.
Deep vein thrombosis, the most common cause of pulmonary embolism, occurs when an
embolus that originated in a deep thigh vein travels up to the lungs and blocks the blood flow
(Fischbein 1981). Pulmonary embolism is an extremely dangerous condition, since it may
cause damage to lung tissue due to a diminished oxygen supply. Additionally, it can damage
other organs due to a lack of oxygen and, in some severe cases, may even cause death.
Pulmonary embolism affects men as well as women. If the pulmonary embolism is caused by
deep vein thrombosis, patients may exhibit symptoms such as
swelling of the leg, pain or tenderness in the leg, or a
discoloration of the skin on the affected area. Pulmonary
embolism is responsible for 10% of all deaths, and an initial
diagnosis is not straightforward. In fact, in 70% of all
If Deep Vein
pulmonary embolism patients, it was not clinically suspected
Affected
but confirmed after an autopsy (Davidson 1999) (Figure 4).
A majority of patients with pulmonary embolism are
Blood clot may
form
treated with anticoagulation medication. Anticoagulation
Danger of clot
therapy is beneficial in the treatment of pulmonary embolism,
traveling
because it provides prophylaxis against further
(embolus) and
blocking lung
thromboembolic events while the body's own fibrinolytic
circulation with
system gradually lyses the embolus. Since dissolving the clot
disastrous
results.
is the treatment for pulmonary embolism, many have
wondered if thrombolytic therapy would be even more
efficient as thrombolytic drugs dissolve clots more rapidly
than endogeneous fibrinolytic activity can. There was a study
comparing the efficacy of recombinant tissue plasminogen
activator and anticoagulants in pulmonary embolism. As part
of the study, 790 stable patients with pulmonary embolism
Inflammation may
travel into abdomen
were randomly assigned to either the heparin (anticoagulant)
Pain in calf
group or the alteplase (recombinant tPA) group. While 169
Leg may swell
patients received recombinant tissue plasminogen activator,
550 patients received heparin alone. The overall 30-day
mortality rate for patients administered tissue plasminogen
Figure 4: Deep vein thrombosis
activator compared to those receiving heparin was 4.7% to
can cause pulmonary embolism
11.1% respectively. Additionally, during the in-hospital
Source: Fischbein 1981
phase, recurrence of pulmonary embolism was more frequent
in patients taking heparin. In fact, the ratio of recurrence was 7.7% to 18.7% in favor of
alteplase (Arcasoy and Kreit 1999).

SYNTHESIS OF THROMBOLYTIC DRUGS
ALTEPLASE
Alteplase is beneficial in thrombolytic treatment because it is easily synthesized using
recombinant DNA technology. The composition of alteplase consists of a purified
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glycoprotein consisting of 527 amino acids. It is synthesized using a complementary DNA
from a human melanoma cell line. Alteplase is manufactured by secretion of an alteplase
enzyme into a culture medium. After secretion of the enzyme, the antibiotic gentamicin is
added to the culture causing fermentation. Gentamicin, however, is not present in the
recombinant tissue plasminogen product. The product also undergoes lyophilization, which is
the process of rapidly freezing and dehydrating in a vacuum (Genetech 2005).
STREPTOKINASE
On the other hand, streptokinase is a drug easily synthesized from a "-hemolytic
streptococcus culture. However, there is a major drawback to using streptokinase. Most
people have had a streptococcal infection at some point in their lives, so they are likely to have
built up antibodies against streptococcal bacteria. Streptokinase is produced from
streptococcal bacteria, so the circulating antibodies are likely to neutralize its effect on the
clots (Finkel et al. 2009). Furthermore, once administered to a patient, streptokinase cannot
be used again for some time due to its antigenic property. Thus, the antigenic property of
streptokinase is one of the most significant detriments to the drug.

MECHANISM OF ACTION
ALTEPLASE
Alteplase has a mechanism of action that makes it fibrin specific and thus favorable for
thrombolytic therapy (Figure 5). First, alteplase attaches to fibrin on the surface of a clot and
initiates fibrin bound plasminogen. Then plasmin is cleaved from the plasminogen associated
with the fibrin, fibrin molecules are broken apart by the plasmin, and the clot dissolves.
Although alteplase has a low attraction for plasminogen in the plasma, it activates
plasminogen attached to fibrin in a blood clot (Klabunde 2005). Alteplase’s fibrin selectivity is
what makes it therapeutically useful. Thus, administering alteplase in low doses lyses only the
wanted clot without degrading other proteins.
STREPTOKINASE
Streptokinase is a protein cultured from the broth of streptococci bacteria. Since
streptokinase is not a protease, it contains no enzymatic activity and has a different
mechanism of action than alteplase. Streptokinase forms an active complex with the
plasminogen (Figure 6). The active complex activates and releases the plasmin to dissolve the
clots (Klabunde 2005). However, streptokinase is not fibrin specific and, therefore, its

Figure 5: (1) Recombinant t-PA (alteplase) binds to fibrin in thrombus
(2) converts entrapped plasminogen to plasmin (3) that initiates local
fibrinolysis.
Source: http://www.cathflo.com/images/moa.gif
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associated plasmin lyses circulating and non-circulating plasminogen. Streptokinase decays
the blood clot as well as important clotting factors, such as Factors V and VII (Finkel et al.
2009).

Figure 6: Streptokinase and its effect on the fibrinolytic system.
Source: http://www.anzcp.org/CCP/Pharmacology/streptokinase_files/image002.gif

PHARMACOKINETICS OF THE THROMBOLYTIC DRUGS
Pharmacokinetics is the pharmacological research of drug movement within the body.
Moreover, it studies the mechanism of absorption, span of drug impact, and chemical
modifications the body experiences. On certain occasions, a drug will be administered
intravenously to ensure that the distribution of medication is instantaneous and efficacious.
The half-life of a medication is the moment it takes a medication to decrease to half its original
potency. Consequently, half-life forecasts the length of time it will take for a drug to leave the
blood plasma. Therefore, if a drug contains a relatively brief half-life, the body disposes and
eliminates that drug quickly. In contrast, when a medication has a prolonged half-life it lingers
in the blood plasma for an extended period of time. Thus, half-life is a good indicator for drug
dosage, because it measures the length of time it takes for the body to dispose of a medication.
While sometimes a short half-life is beneficial for patients, other times a long half-life is
advantageous for a patient.
HALF-LIFE OF THROMBOLYTIC DRUGS
Alteplase has an extremely brief half-life of approximately five minutes. There is an
advantage and a disadvantage to the short half-life in alteplase. An advantage is that alteplase
is a powerful clot busting medication that lyses only a specific clot and is eliminated from the
body in a very brief time. A disadvantage of alteplase’s short half-life is the increased
possibility of reocclusion (Greer 2007). In contrast, streptokinase has a much longer half-life
than that of alteplase. However, the longer half-life of streptokinase also has disadvantages,
since streptokinase has antigenic properties and poses the risk of other allergic reactions.
Additionally, it is usually unsafe to administer streptokinase a second time within 6 months
due to its highly antigenic property (Rivera-Bou and Brown 2010).

CONCLUSION

The Food and Drug Administration approved alteplase as a treatment for acute
ischemic stroke on June 8, 1996. Astonishingly, to this very day, alteplase is the sole approved
medication for patients suffering from ischemic stroke. Additionally, it has bumped stroke
from the third leading cause of death to the fourth leading cause of death in the United States
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(Center for Disease Control 2010). The Gusto-I and Gusto-III trials indicate that alteplase is
a more practical and powerful drug than streptokinase in patients suffering from myocardial
infarction with ST segmentation. In fact, according to the American Heart Association, the
ideal time to administer thrombolytic drugs is within 90 minutes after the heart attack.
However, if administered up to 12 hours after the onset of symptoms, the chances of surviving
and recovering are still enhanced (Health Guide 2010).
Pulmonary embolism is not an easily detected condition, but deep vein thrombosis, an
equally serious condition, is detectable. The use of alteplase in acute massive pulmonary
embolism has shown more efficient and steadfast results than that of anticoagulation therapy.
Due to an extremely brief half-life, possibly resulting in reocclusion, alteplase has come under
fire. However, with the use of recombinant technology, more generations of alteplase are
being synthesized and produced to enhance the already proficient drug.
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